Ribonucleotide reductase: An old target with new potential

Leukemia Research

Volumn 27, Issue 12, 2003, Pages 1075-1076

  Smith, B Douglas ^a   Karp, Judith E ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; ANTINEOPLASTIC AGENT; BICARBONATE; CLADRIBINE; CLOFARABINE; CYTARABINE; DEOXYRIBONUCLEOTIDE; DNA; ENZYME INHIBITOR; FLUDARABINE; HYDROXYUREA; PROTEIN SUBUNIT; RIBONUCLEOTIDE; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE INHIBITOR; UNCLASSIFIED DRUG; VANCOMYCIN;

ACUTE GRANULOCYTIC LEUKEMIA; BINDING SITE; CANCER CHEMOTHERAPY; CELL CYCLE; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC GRANULOCYTIC LEUKEMIA; CLINICAL TRIAL; CYTOTOXICITY; DNA DAMAGE; DNA REPAIR; DNA SYNTHESIS; DRUG POTENCY; ENZYME INHIBITION; HUMAN; LEUKOCYTE COUNT; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NOTE; PALLIATIVE THERAPY; PRIORITY JOURNAL; SPLENOMEGALY;

EID: 0042062334     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(03)00248-0     Document Type: Article

References (9)

1. Reichard P., Ehrenberg A. Ribonucleotide reductase - a radical enzyme. Science. 221:1983;514-519.
2. Mann G.J., Musgrove E.A., Fox R.M., Thelander L. Ribonucleotide reductase M1 subunit in cellular proliferation, quiescence, and differentiation. Cancer Res. 48:1988;5151-5156.
3. Rauscher F. III, Cadman E. Biochemical and cytokinetic modulation of L1210 and HL-60 cells by hydroxyurea and effect on 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity. Cancer Res. 43:1983;2688-2693.
4. Crews K.R., Gandhi V., Srivastava D.K.et al. Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia. J. Clin. Oncol. 20:2002;4217-4224.
5. Estey E.H., Thall P.F., Cortes J.E.et al. Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood. 98:2001;3575-3583.
6. Steinmetz H.T., Schulz A., Staib P.et al. Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML. Ann. Hematol. 78:1999;418-425.
7. McCarthy A.J., Pitcher L.A., Hann I.M., Oakhill A. FLAG (fludarabine, high-dose cytarabine, and G-CSF) for refractory and high-risk relapsed acute leukemia in children. Med. Pediatr. Oncol. 32:1999;411-415.
8. Finch R.A., Liu C., Cory A.H., Cory J.G., Sartorelli A.C. Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP): an inhibitor of ribonucleotide reductase with antineoplastic activity. Adv. Enzyme Regul. 39:1999;3-12.
9. Liu H., Ding R., Jiang S.et al. Suppression of haematopoiesis by sera from patients with aplastic anemia. Tokushima J. Exp. Med. 43:1996;107-111.